Verona Pharma plc Verona Pharma To Present At Jefferies 2019 Global Healthcare Conference

 
TIDMVRP 
 
   LONDON, May 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, today announces that the 
Company's management team will present and conduct face-to-face meetings 
at the Jefferies 2019 Global Healthcare Conference. 
 
   Presenter:      Jan-Anders Karlsson, PhD, CEO 
 
   Date:               Wednesday, June 5(th) 
 
   Time:               8:30 AM EDT 
 
   Location:        New York, NY 
 
   For more information, please visit 
https://www.globenewswire.com/Tracker?data=XsMqF6R2JYklWHKj8Sl84T5tURKNBTsG9HOwNFee8PAPBxCR3dttsOz6IVQN--LfBKstIU1AN-yPHQeKT_s6X2PFwGBtji5gGfm5XW18LsMfiEgN-eWz2i28-u43TYDo 
investors.veronapharma.com. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, 
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that 
has been shown to act as both a bronchodilator and an anti-inflammatory 
agent in a single compound. Nebulized ensifentrine is currently in Phase 
2b clinical development for the maintenance treatment of COPD and is 
planned to enter Phase 3 trials for this indication in 2020. Verona 
Pharma plans a targeted US launch of the nebulized formulation, which is 
expected to benefit from a simplified Medicare Part B reimbursement 
process in the US. Verona Pharma may also develop ensifentrine for the 
treatment of cystic fibrosis and asthma. 
 
   Ensifentrine has shown significant and clinically meaningful 
improvements in both lung function and COPD symptoms, including 
breathlessness in prior Phase 2 clinical studies in patients with 
moderate-to-severe COPD. In addition, ensifentrine has further improved 
lung function and reduced lung volumes in patients taking standard 
short- and long-acting bronchodilator therapy, including maximum 
bronchodilator treatment with dual/triple therapy. Ensifentrine has been 
well tolerated in clinical trials involving more than 800 people to 
date. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements, 
including, but not limited to, the future clinical development and 
positioning of ensifentrine and the expected timelines for the Phase 3 
trials of ensifentrine. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, the 
following: our limited operating history; our need for additional 
funding to complete development and commercialization of ensifentrine, 
which may not be available and which may force us to delay, reduce or 
eliminate our development or commercialization efforts; the reliance of 
our business on the success of ensifentrine, our only product candidate 
under development; economic, political, regulatory and other risks 
involved with international operations; the lengthy and expensive 
process of clinical drug development, which has an uncertain outcome; 
serious adverse, undesirable or unacceptable side effects associated 
with ensifentrine, which could adversely affect our ability to develop 
or commercialize ensifentrine; potential delays in enrolling patients, 
which could adversely affect our research and development efforts; we 
may not be successful in developing ensifentrine for multiple 
indications; our ability to obtain approval for and commercialize 
ensifentrine in multiple major pharmaceutical markets; misconduct or 
other improper activities by our employees, consultants, principal 
investigators, and third-party service providers; material differences 
between our "top-line" data and final data; our reliance on third 
parties, including clinical investigators, manufacturers and suppliers, 
and the risks related to these parties' ability to successfully develop 
and commercialize ensifentrine; and lawsuits related to patents covering 
ensifentrine and the potential for our patents to be found invalid or 
unenforceable. These and other important factors under the caption "Risk 
Factors" in our Annual Report on Form 20-F filed with the Securities and 
Exchange Commission ("SEC") on March 19, 2019, and our other reports 
filed with the SEC, could cause actual results to differ materially from 
those indicated by the forward-looking statements made in this press 
release. Any such forward-looking statements represent management's 
estimates as of the date of this press release. While we may elect to 
update such forward-looking statements at some point in the future, we 
disclaim any obligation to do so, even if subsequent events cause our 
views to change. These forward-looking statements should not be relied 
upon as representing our views as of any date subsequent to the date of 
this press release. 
 
 
 
 
For further information, please contact: 
Verona Pharma plc                                         Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer              info@veronapharma.com 
 
N+1 Singer                                                Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) 
 Mia Gardner (Corporate Broking) 
 
Optimum Strategic Communications                          Tel: +44 (0) 203 922 0891 
 (European Media and Investor enquiries)                   verona@optimumcomms.com 
Mary Clark, Anne Marieke Ezendam, Hollie Vile 
 
Westwicke, an ICR Company                                 Tel. +1 646-277-1282 
 (US Investor enquiries)                                   Stephanie.Carrington@icrinc.com 
Stephanie Carrington
(END) Dow Jones Newswires
May 30, 2019 02:00 ET (06:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024